Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment

<div>(a) Central subfield thickness (CST), (b) subfoveal choroidal thickness (SFCT), and (c) best-corrected visual acuity (BCVA) changes in each spironolactone-treated eye.</div>

Journal of Ophthalmology

fig5

Figure 5

Figure 5: Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment 

Figure 5 | Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment 